Who Paid My Doc
Frank Sciurba
Pittsburgh, PA Medical Doctor
NPI 1285609545 CMS profile 13173
3601 5Th Ave, 4Th Floor Falk, Comprehensive Lung Center, Pittsburgh, PA 15213
General payments
$118,920
Research payments
$3,866
Ownership & investment interest
$0
Research they led as principal investigator
$1,092,731
Through program year 2025, Frank Sciurba of Pittsburgh, PA is reported in the CMS Open Payments database as having received $118,920 across 124 general payments and $3,866 in research payments paid to them. Separately, studies naming them as principal investigator received $1,092,731 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $36,552 | 41 | |
| 2025 | Research | $2,360 | 12 | |
| 2024 | General | $30,581 | 25 | |
| 2023 | General | $32,862 | 31 | |
| 2022 | General | $10,612 | 18 | |
| 2019 | General | $8,313 | 9 | |
| 2019 | Research | $1,506 | 15 |
Beside peers
- Frank Sciurba
- Pennsylvania median
- Middle half of Pennsylvania
- National median
In program year 2025, general payments to Frank Sciurba were reported at $36,552. Among 44,217 Pennsylvania profiles paid that year, the median was $168 and the middle half received between $50 and $597.
Show as a table
| Year | Frank Sciurba | Pennsylvania median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $8,313 | $156 | $46–$628 | $163 |
| 2020 | $0 | $109 | $33–$381 | $114 |
| 2021 | $0 | $125 | $35–$469 | $132 |
| 2022 | $10,612 | $136 | $40–$499 | $149 |
| 2023 | $32,862 | $147 | $46–$523 | $160 |
| 2024 | $30,581 | $156 | $46–$568 | $164 |
| 2025 | $36,552 | $168 | $50–$597 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
618
Drug cost
$589,584
Branded share of claims
77.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Prolastin C Alpha-1-Proteinase Inhibitor | Brand | 24 | $252,351 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 163 | $137,368 | |
| Nucala Mepolizumab | Brand | 15 | $53,783 | |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | Brand | 65 | $40,083 | |
| Dupixent Pen Dupilumab | Brand | 11 | $39,534 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 37 | $24,591 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 26 | $22,529 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 12 | $4,217 | |
| Incruse Ellipta Umeclidinium Bromide | Brand | 12 | $3,875 | |
| Alvesco Ciclesonide | Brand | 12 | $3,024 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 17 billing codesPaid by Medicare
$6,678
Medicare patients
53
Services billed
87
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| COPD | 75% | |
| Arthritis | 53% | |
| Ischemic heart disease | 49% | |
| Depression | 47% | |
| Heart failure | 38% | |
| Atrial fibrillation | 36% | |
| Diabetes | 30% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
151 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.